WO2009134767A1 - Préservatif avec un agent actif local - Google Patents

Préservatif avec un agent actif local Download PDF

Info

Publication number
WO2009134767A1
WO2009134767A1 PCT/US2009/041930 US2009041930W WO2009134767A1 WO 2009134767 A1 WO2009134767 A1 WO 2009134767A1 US 2009041930 W US2009041930 W US 2009041930W WO 2009134767 A1 WO2009134767 A1 WO 2009134767A1
Authority
WO
WIPO (PCT)
Prior art keywords
condom
bead
wax
elastomeric layer
active ingredient
Prior art date
Application number
PCT/US2009/041930
Other languages
English (en)
Inventor
Beng Sim Chuah
Tsui Shih Yeun
David M. Lucas
Burton Van Rooyen
Michael S. Zedalis
Original Assignee
Ansell Healthcare Products Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/427,061 external-priority patent/US20100263675A1/en
Application filed by Ansell Healthcare Products Llc filed Critical Ansell Healthcare Products Llc
Priority to CN2009801248887A priority Critical patent/CN102083395A/zh
Priority to AU2009241580A priority patent/AU2009241580A1/en
Priority to BRPI0911573A priority patent/BRPI0911573A2/pt
Priority to JP2011507572A priority patent/JP2011518646A/ja
Priority to EP09739569A priority patent/EP2280674A1/fr
Priority to MX2010011780A priority patent/MX2010011780A/es
Priority to CA2725428A priority patent/CA2725428A1/fr
Publication of WO2009134767A1 publication Critical patent/WO2009134767A1/fr
Priority to IL209029A priority patent/IL209029A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F6/00—Contraceptive devices; Pessaries; Applicators therefor
    • A61F6/02—Contraceptive devices; Pessaries; Applicators therefor for use by males
    • A61F6/04—Condoms, sheaths or the like, e.g. combined with devices protecting against contagion
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants

Definitions

  • Embodiments of the present invention relate to condoms having an active ingredient localized in the closed end of a condom.
  • condoms having one or more active ingredients solubilized or mixed as a fine water soluble powder within a low melting wax bead.
  • Ingredients for example, include liquid nonoxynol-9 and other spermicides, as well as niacin, nitroglycerin, and sildenafil citrate, and other vasodilators.
  • BACKGROUND [0002]
  • Condoms and other prophylactics and protective devices provide physical barriers against the transmission of bodily fluids or other fluids. Chemical barriers can be also used alone or in conjunction with condoms to prevent such transmission.
  • U.S. Patent No. 5,284,158 provides a sensitive condom that locates a spermicide in a latex cap of a condom as well as in a space between the main sheath of the condom and a reinforcing membrane.
  • the packaging of Mallette moreover, includes the spermicide to prevent drying of the membrane.
  • U.S. Patent No. 4,795,425 a double dosage of spermicide is provided, where a first dosage is provided in a semi-solid state in the closed end of the condom and a second dosage is provided on the outside surface of the condom.
  • the semi-solid dosage is provided as a cream or ointment where the spermicide is mixed with forms of polyethylene glycol, including Carbowax 400, which is not a solid wax at room temperature, and Carbowax 3350, which is solid and has a melting point in the range of 54°C to 57°C. Such a cream or ointment is stated to have a melting point in the range of 113- 127°F (45-53°C).
  • Spermicides such as nonoxynol-9, however, have been identified as possible irritants to mucosal membranes.
  • U.S. Patent No. 5,387,611 (Rubinstein) provides non- irritating agents having anti-bacterial and anti-viral activity using butylurea in combination with nonoxynol-9 and/or benzalkonium chloride.
  • condoms can be used to deliver therapeutic agents such as vasodilators and erectogenic compounds.
  • an erectogenic compound is immobilized in the closed end of a condom by the use of a solvent carrier, in the optional presence of a film- forming agent, which is subsequently evaporated to leave the erectogenic compound in a finely-divided form or as a film layer.
  • a condom has a first lubricating composition having a relatively high viscosity and containing a male genitalia desensitizing agent located on the inside surface and a second lubricating composition having a lower viscosity on the outside surface.
  • Particles of wax can be used in coatings on elastomeric articles to aid in donning or blocking, as provided in, for example, U.S. Patent Nos. 5,405,666 (Brindle); 6,075,081 (Nile); and 6,306,514 (Weikel). Such use of wax, however, does not provide localized delivery of an active ingredient.
  • a condom having an elastomeric layer and a low melt wax bead which comprises an active ingredient mixed therein, wherein the bead is affixed on the interior surface of the elastomeric layer in the tip of the condom.
  • a condom comprises an elastomeric layer and a low melt wax bead which comprises nonoxynol-9 mixed therein.
  • a male desensitizing agent mixed into the bead, for example benzocaine, dibucaine, lidocaine, tetracaine, and salts and derivatives thereof.
  • a condom comprising the steps of: providing a molten solution of a low melt wax containing an active ingredient; providing the condom; dropping a bead of the molten solution on the interior surface and in the tip of the condom; permitting the bead to reach ambient temperature and solidifying the bead such that the bead is localized on the interior surface and in the tip of the condom; and packaging the condom.
  • the step of providing the molten solution can comprise melting the low melt wax and mixing the active ingredient having a melting point less than that of the low melt wax with the low melt wax to form a substantially uniform molten solution.
  • Such step can comprise melting the wax and adding a fine powder of water soluble active agent.
  • Further aspects include methods for providing a spermicide within the closed end of the condom, the methods comprising providing a condom which comprises an elastomeric layer and a low melt wax bead which comprises nonoxynol-9 mixed therein, the bead comprising a natural wax modified to have a melting point in the range of 25°C to 40 0 C and a polyethylene glycol polymer with an appropriate molecular weight to have a melting point in the range of 25°C to 40 0 C, wherein the bead is affixed on the interior surface of the elastomeric layer in the tip of the condom and wherein the exterior surface of the elastomeric layer is substantially free of nonoxynol-9.
  • Further aspects include methods for providing an erectogenic compound within the closed end of the condom, the methods comprising providing a condom which comprises an elastomeric layer and a low melt wax bead which comprises an erectogenic compound mixed therein, the bead comprising a natural wax modified to have a melting point in the range of 25°C to 40 0 C and a polyethylene glycol polymer with an appropriate molecular weight to have a melting point in the range of 25°C to 40 0 C, wherein the bead is affixed on the interior surface of the elastomeric layer in the tip of the condom and wherein the exterior surface of the elastomeric layer is substantially free of the erectogenic compound.
  • a condom which comprises an elastomeric layer and a low melt wax bead which comprises an erectogenic compound mixed therein
  • the bead comprising a natural wax modified to have a melting point in the range of 25°C to 40 0 C and a polyethylene glycol polymer
  • a condom delivery of an active ingredient via a condom can be achieved by localizing the active ingredient using a bead of wax or other suitable carrier in the tip of the condom on its interior surface.
  • the active ingredient can be delivered in a diluted, yet still effective form, to reduce irritation.
  • location of the active ingredient in the interior of the condom reduces exposure of the users' partner to the active ingredient.
  • Use of a low melting wax, for example, permits substantially uniform distribution of the active ingredient incorporated in the bead to further aid in effective delivery of the ingredient.
  • condoms having an elastomeric layer and a low melt wax bead which comprises an active ingredient mixed therein, wherein the bead is affixed on the interior surface of the elastomeric layer in the tip of the condom.
  • the exterior surface of the elastomeric layer is substantially free of the active ingredient.
  • substantially free of the active ingredient it is meant that the exterior surface of the elastomeric layer is not provided with the active ingredient nor is there a significant amount of active ingredient on the exterior surface. It is recognized that as a result of the handling of the condom miniscule amounts of active ingredient may inadvertently reside on the exterior surface.
  • references to "low melt” refers to a material, such as wax or other suitable carrier that softens, flattens, and/or melts in the presence of body heat, which is approximately 37°C.
  • the bead softens in the presence of body heat thereby substantially exposing the active ingredient.
  • the wax or other suitable carrier melts in the range of 25°C- 40 0 C.
  • the active ingredient comprises a spermicide.
  • the spermicide comprises nonoxynol-9.
  • Other spermicides include oxtoxynol-9, menfegol, a vaginal contraceptive compound with a surface active agent p- menthanylphenyl polyoxyethylene ether, lactic acid, neem oil, membrane disruptive agents, derivatives thereof, and combinations thereof.
  • the active ingredient comprises a vasodilator.
  • the vasodilator comprises a niacin component.
  • a niacin component includes niacin (also known as nicotinic acid), nicotinamide, methyl nicotinate (niacin methyl ester), derivatives thereof, or combinations thereof.
  • niacin also known as nicotinic acid
  • nicotinamide also known as nicotinamide
  • methyl nicotinate niacin methyl ester
  • derivatives thereof or combinations thereof.
  • Embodiments of the present invention can utilize selective inhibitors of phosphodiesterase, for example, cyclic guanosine monophosphate (cGMP) specific phosphodiesterase type 5 ("PDE-5").
  • PDE-5 inhibitors include, but are not limited to, sildenafil, tadalafil, vardenafil, derivatives, and pharmaceutically acceptable salts thereof.
  • Other suitable vasodilators include prostaglandin compounds, for example prostaglandin E-I, which is known under the pharmaceutical name of alprostadil. Another suitable ingredient is testosterone.
  • Other embodiments may include compounds which have vasodilatory effects which include niacin, L-arginine, ginger, menthol, menthyl lactate, and other menthol derivatives and precursors, compounds such as peppermint, spearmint and other mint oils, nitric oxide, precursors of nitric oxide, i.e., glyceryl trinitrate (nitroglycerin), organic nitrites, i.e., amyl nitrite, isoamyl nitrite and the like, and variations thereof, while other embodiments utilize other vasodilators known in the art.
  • compounds which have vasodilatory effects which include niacin, L-arginine, ginger, menthol, menthyl lactate, and other menthol derivatives and precursors, compounds such as peppermint, spearmint and other mint oils, nitric oxide, precursors of nitric oxide, i.e., glyceryl trinit
  • the elastomeric layer is comprised of natural rubber latex, synthetic polyisoprene, guayule, polyurethane, copolymers or combinations thereof.
  • natural rubber latex encompasses cured elastomeric material sourced from Hevea brasiliensis (the traditional rubber tree), Parthenium argentatum (guayule), sunflower, goldenrod and the like, as well as genetically modified variations of these or other biological sources.
  • Other embodiments utilize other substances to form the elastomeric layer that are known in the art.
  • the bead may include waxes that are either synthetic or natural.
  • the natural waxes that may be generally used include montan, carnauba, bees wax, bayberry-myrtle, candelialla, caranday, castor bean, asparto-grass, Japan, ouricury, retamo-ceri, mimbi, schlack, spermaceti, sugar-cane, and wool lanolin.
  • Synthetic waxes generally include polyethylene and modified polyethylenes, polypropylene and modified polypropylenes, and hydrogen-based materials.
  • the bead can comprise polyethylene glycol (PEG).
  • PEG polyethylene glycol
  • the bead comprises one or more polyethylene glycol polymers having an overall molecular weight in the range of 400 to 1500 (or 600 to 1300, or even 800-1100) and having a melting point in the range of 25°C to 40 0 C (or even 36-39°C).
  • An additional PEG is PEG 1000, which has a melting point of 38°C, which is suited for localized incorporation of active ingredients of the present invention.
  • a polyethylene glycol-based wax containing PEG-6 and PEG-32 which has a molecular weight in the range of 470 - 530 g/mol, may also be suitable.
  • PEG-containing bead it is expected that upon contact skin-generated moisture, warming occurs due to an exothermic heat of dissolution on the order of an increase in temperature of about 5-7°C. The warming effect can help enlarge skin pores and enhance penetration of the active ingredient.
  • the exterior surface of the condom contains a lubricant.
  • This lubricant can contain silicone or any other lubricating material that is compatible and not miscible with the wax bead. With reference to compatible, it is meant that the lubricating material would not destabilize the wax bead or cause the active agent to be released if the lubricating material contacts the wax bead.
  • Suitable lubricants can include silicone oils such as dimethicone, dimethylsiloxane, cyclomethicone and other silicone derivatives and other non-PEG wax solubilizing materials. This lubricant can further contain materials that enhance the sexual experience for the female and/or alleviate symptoms associated with female sexual dysfunction.
  • Such materials include, but are not limited to: L- arginine; menthol, menthyl lactate, and other menthol derivatives and precursors; a prostaglandin compound, such as prostaglandin E-I, which is known under the pharmaceutical name of alprostadil.
  • a prostaglandin compound such as prostaglandin E-I, which is known under the pharmaceutical name of alprostadil.
  • Another possible addition to the lubricant is an astringent such as witch hazel.
  • the interior surface of the condom further contains a lubricant that is free of the active agent.
  • This lubricant can contain silicone or any other lubricating material that is compatible and not miscible with the wax bead. If a lubricant on the exterior surface is provided, then typically the lubricant on the interior surface is of a higher viscosity that that on the exterior surface.
  • condoms comprising an elastomeric layer and a low melt wax bead which comprises nonoxynol-9 mixed therein, the bead comprising a modified natural wax and a polyethylene glycol polymer wax with appropriate molecular weight and melting point, wherein the bead is affixed on the interior surface of the elastomeric layer in the tip of the condom and wherein the exterior surface of the elastomeric layer is substantially free of nonoxynol-9.
  • the bead nonoxynol-9 mixed therein is present in an amount in the range of 10 to about 100 mg.
  • the wax bead may be up to 1 gram or more.
  • the active ingredient may be desirable to provide the active ingredient in an amount in the range of 1 to 1 1 A the dosage needed, rather than an excess of 3 times or more of the required dosage, which is the amount of nonoxynol-9 generally needed in a water based or silicone based lubricant.
  • Additional aspects include methods for providing a spermicide in the closed end of a condom, the methods comprising providing a condom which comprises an elastomeric layer and a low melt wax bead which comprises nonoxynol-9 mixed therein, the bead comprising a modified natural wax and a polyethylene glycol polymer wax with appropriate molecular weight and melting point, wherein the bead is affixed on the interior surface of the elastomeric layer in the tip of the condom and wherein the exterior surface of the elastomeric layer is substantially free of nonoxynol-9.
  • Further embodiments of the present invention include a packaging containing the condom, as otherwise described herein.
  • the materials used in forming the package are selected from materials that can form packages that are substantially impermeable to the passage of air and moisture.
  • the packaging materials include, but are not limited to, cellulosic materials, such as paper or paperboard; polymeric films and sheeting; metallic foils; and composite materials formed from two or more of these materials.
  • the packages may be sealed by bonding processes including, but not limited to, adhesive, heat, ultrasonic welding, pressure and combinations of these bonding processes.
  • EXAMPLE IA A modified natural wax and polyethylene glycol polymer wax with appropriate molecular weight and melting point formulation is melted to bring the wax few degrees ( ⁇ 1- 10 0 C) above the melting point, to which 100 mg nonoxynol-9 liquid is added to form a mixture. A bead of the mixture is dropped into the tip of a condom on the interior surface and is allowed to reach ambient temperature and solidify the wax bead. The condom is then packaged. Nonoxynol-9 can be dosed up to 15 to 20% of the weight of the wax.
  • a modified natural wax and polyethylene glycol polymer wax with appropriate molecular weight and melting point formulation is melted to bring the wax few degrees ( ⁇ 1- 10 0 C) above the melting point, to which 100 mg nitroglycerin liquid is added to form a mixture.
  • a bead of the mixture is dropped into the tip of a condom on the interior surface and is allowed to reach ambient temperature and solidify the wax bead. The condom is then packaged.
  • a polyethylene glycol polymer wax (PEG 1000) with appropriate molecular weight and melting point formulation is melted to bring the wax few degrees ( ⁇ l-10°C) above the melting point, to which 100 mg of finely powdered water-soluble niacin is added to form a mixture.
  • a bead of the mixture is dropped into the tip of a condom on the interior surface and is allowed to reach ambient temperature and solidify the wax bead. The condom is then packaged.
  • a 1 gram wax bead may contain 5% niacin resulting in 50 mg of niacin.
  • EXAMPLE 3B A polyethylene glycol polymer wax mixed with glycerin and containing 0.25% menthol was heated, to which 20 mg of finely powdered water-soluble niacin was added to form a mixture. A bead of the mixture was dropped into the tip of a condom on the interior surface and was allowed to reach ambient temperature and solidify the wax bead. Tests were conducted with 2% or 20 mg of niacin incorporated within the wax bead providing effective performance.
  • EXAMPLE 4 A polyethylene glycol polymer wax mixed with glycerin and containing 0.25% menthol was heated, to which 20 mg of finely powdered water-soluble niacin was added to form a mixture. A bead of the mixture was dropped into the tip of a condom on the interior surface and was allowed to reach ambient temperature and solidify the wax bead. Tests were conducted with 2% or 20 mg of niacin incorporated within the wax bead providing effective performance.
  • a modified natural wax and polyethylene glycol polymer wax with appropriate molecular weight and melting point formulation is melted to bring the wax few degrees ( ⁇ 1- 10 0 C) above the melting point, to which 100 mg of finely powdered water soluble sildenafil citrate is added to form a mixture.
  • a bead of the mixture is dropped into the tip of a condom on the interior surface and is allowed to reach ambient temperature. The condom is then packaged.
  • a 1% concentration of sildenafil citrate in a 1 gram wax bead will deliver 10 mg of sildenafil citrate.
  • EXAMPLE 5 A mixture of polyethylene glycol polymer waxes with appropriate molecular weight and melting points is melted to bring the wax few degrees ( ⁇ l-10°C) above the melting point, to which 10-100 mg of powdered benzocaine is added to form a mixture. A bead of the mixture is dropped into the tip of a condom on the interior surface and is allowed to reach ambient temperature. The condom is then packaged.
  • EXAMPLE 6 A mixture of polyethylene glycol polymer waxes with appropriate molecular weight and melting points is melted to bring the wax few degrees ( ⁇ l-10°C) above the melting point, to which 10-100 mg of powdered benzocaine is added to form a mixture. A bead of the mixture is dropped into the tip of a condom on the interior surface and is allowed to reach ambient temperature. The condom is then packaged.
  • PEG-32 is sold under the product name Lanogen 1500 by Clariant, was melted to bring the wax few degrees ( ⁇ l-10°C) above the melting point, to which 1-3% by weight of methyl nicotinate and 0.001 to 0.005 % by weight of menthol crystal (menthol L) were added to form a mixture.
  • a 0.5 to 2 gram bead of the mixture was dropped into the tip of a condom on the interior surface and was allowed to reach ambient temperature.
  • a silicone oil was applied to the exterior surface of the condom in an amount in the range of 0.2 to 1 gram.
  • EXAMPLE 7 A product having a mixture of polyethylene glycol waxes, PEG-6 and PEG-32 is sold under the product name Lanogen 1500 by Clariant, was melted to bring the wax few degrees ( ⁇ l-10°C) above the melting point, to which 1-3% by weight of methyl nicotinate and 2-5 % by weight of liquid menthol lactate were added to form a mixture. A 0.5 to 2 gram bead of the mixture was dropped into the tip of a condom on the interior surface and was allowed to reach ambient temperature. A silicone oil was applied to the exterior surface of the condom in an amount in the range of 0.2 to 1 gram.

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Reproductive Health (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Medicinal Preparation (AREA)
  • Lubricants (AREA)
  • Compositions Of Macromolecular Compounds (AREA)

Abstract

La présente invention concerne des préservatifs et des procédés de fabrication et d'utilisation de ceux-ci, les préservatifs ayant une couche élastomère et une bille de cire à bas point de fusion à l’intérieur de laquelle est mélangé un principe actif, la bille étant fixée sur la surface intérieure de la couche élastomère dans l’extrémité du préservatif. Les principes actifs peuvent comprendre des spermicides tels que le nonoxynol-9 et des vasodilatateurs tels que la niacine, le citrate de sildénafil, et la nitroglycérine et des agents de désensibilisation pour les hommes tels que la benzocaïne. La bille peut comprendre une cire naturelle en combinaison avec du polyéthylène glycol ou peut être une cire à base de polyéthylène glycol. La surface extérieure de la couche élastomère est sensiblement dépourvue de principe actif.
PCT/US2009/041930 2008-04-29 2009-04-28 Préservatif avec un agent actif local WO2009134767A1 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
CN2009801248887A CN102083395A (zh) 2008-04-29 2009-04-28 具有局部化的活性剂的避孕套
AU2009241580A AU2009241580A1 (en) 2008-04-29 2009-04-28 Condom with localized active agent
BRPI0911573A BRPI0911573A2 (pt) 2008-04-29 2009-04-28 preservativo com agente ativo localizado.
JP2011507572A JP2011518646A (ja) 2008-04-29 2009-04-28 局在活性剤を有するコンドーム
EP09739569A EP2280674A1 (fr) 2008-04-29 2009-04-28 Préservatif avec un agent actif local
MX2010011780A MX2010011780A (es) 2008-04-29 2009-04-28 Condon con agente activo localizado.
CA2725428A CA2725428A1 (fr) 2008-04-29 2009-04-28 Preservatif avec un agent actif local
IL209029A IL209029A0 (en) 2008-04-29 2010-10-31 Condom with localized active agent

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US4894608P 2008-04-29 2008-04-29
US61/048,946 2008-04-29
US12/427,061 US20100263675A1 (en) 2009-04-21 2009-04-21 Condom with Localized Active Agent
US12/427,061 2009-04-21

Publications (1)

Publication Number Publication Date
WO2009134767A1 true WO2009134767A1 (fr) 2009-11-05

Family

ID=41255377

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/041930 WO2009134767A1 (fr) 2008-04-29 2009-04-28 Préservatif avec un agent actif local

Country Status (12)

Country Link
EP (1) EP2280674A1 (fr)
JP (1) JP2011518646A (fr)
KR (1) KR20100134782A (fr)
CN (1) CN102083395A (fr)
AR (1) AR071233A1 (fr)
AU (1) AU2009241580A1 (fr)
BR (1) BRPI0911573A2 (fr)
CA (1) CA2725428A1 (fr)
IL (1) IL209029A0 (fr)
MX (1) MX2010011780A (fr)
RU (1) RU2010148432A (fr)
WO (1) WO2009134767A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10842664B2 (en) 2015-10-29 2020-11-24 Arizona Board Of Regents On Behalf Of Arizona State University Skin-like condoms having active ingredients to enhance a male erection and a female arousal

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104161617A (zh) * 2014-08-29 2014-11-26 蔺莹莹 一种新型避孕套及其制备方法
CN104921862B (zh) * 2015-05-25 2018-03-27 广州朗圣药业有限公司 定量润滑避孕套
US20160374849A1 (en) * 2015-06-24 2016-12-29 Ansell Limited Packaged silicone lubricated condom that provides sensation
KR102161121B1 (ko) * 2018-11-28 2020-09-29 이성준 캡슐형 윤활제가 포함된 콘돔 세트
CN110123511B (zh) * 2019-04-30 2021-05-28 广州万方健医药有限公司 一种防滑脱避孕套

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040265400A1 (en) * 2003-02-07 2004-12-30 Barone Frank V Compositions for enhancing sexual responsiveness
US6840244B2 (en) * 2001-03-30 2005-01-11 Futura Medical Developments Limited Condom with an erectogenic composition
US20050076916A1 (en) * 2002-04-16 2005-04-14 James Barder Condom
US20050182076A1 (en) * 2004-02-13 2005-08-18 Adam A. Pachelo (Ano) Tina Weiss Transdermal penetration system and treatment for cellulite
US20070004785A1 (en) * 2005-06-15 2007-01-04 Hydra Biosciences, Inc. Modulators of sperm hypermotility and uses thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6840244B2 (en) * 2001-03-30 2005-01-11 Futura Medical Developments Limited Condom with an erectogenic composition
US20050076916A1 (en) * 2002-04-16 2005-04-14 James Barder Condom
US20040265400A1 (en) * 2003-02-07 2004-12-30 Barone Frank V Compositions for enhancing sexual responsiveness
US20050182076A1 (en) * 2004-02-13 2005-08-18 Adam A. Pachelo (Ano) Tina Weiss Transdermal penetration system and treatment for cellulite
US20070004785A1 (en) * 2005-06-15 2007-01-04 Hydra Biosciences, Inc. Modulators of sperm hypermotility and uses thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10842664B2 (en) 2015-10-29 2020-11-24 Arizona Board Of Regents On Behalf Of Arizona State University Skin-like condoms having active ingredients to enhance a male erection and a female arousal

Also Published As

Publication number Publication date
RU2010148432A (ru) 2012-06-10
MX2010011780A (es) 2010-12-17
AR071233A1 (es) 2010-06-02
KR20100134782A (ko) 2010-12-23
BRPI0911573A2 (pt) 2016-01-05
CN102083395A (zh) 2011-06-01
EP2280674A1 (fr) 2011-02-09
JP2011518646A (ja) 2011-06-30
CA2725428A1 (fr) 2009-11-05
AU2009241580A1 (en) 2009-11-05
IL209029A0 (en) 2011-01-31

Similar Documents

Publication Publication Date Title
US20100263675A1 (en) Condom with Localized Active Agent
EP2280674A1 (fr) Préservatif avec un agent actif local
US8770201B2 (en) Condom with multifunctional coating
AU2009202895B2 (en) Warming and nonirritating lubricant compositions and method of comparing irritation
AU2002242875C1 (en) Condom with an erectogenic composition
JP2008531497A (ja) 増粘展延性昇温潤滑剤
JPS5892350A (ja) 殺精子剤付きコンド−ム
EP1003448B1 (fr) Preservatifs plus surs
JP2008531085A (ja) 展延性昇温潤滑剤
AU2002242875A1 (en) Condom with an erectogenic composition
US20110284010A1 (en) Condom with coating having capsules
TW200400023A (en) Condom
WO2017075460A1 (fr) Préservatifs de type peau ayant des principes actifs pour améliorer l'érection masculine et l'excitation féminine
CN104161617A (zh) 一种新型避孕套及其制备方法

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980124888.7

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09739569

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2011507572

Country of ref document: JP

Ref document number: 2725428

Country of ref document: CA

Ref document number: MX/A/2010/011780

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2009241580

Country of ref document: AU

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 7946/DELNP/2010

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 589406

Country of ref document: NZ

Ref document number: 2009739569

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20107026233

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2009241580

Country of ref document: AU

Date of ref document: 20090428

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2010148432

Country of ref document: RU

ENP Entry into the national phase

Ref document number: PI0911573

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20101028